Otolith Labs, a medical technology company developing noninvasive wearable medical devices for the treatment of vestibular disorders, announced the closing of a $20 million Series A financing round by Morningside Ventures.

Building on prior investments from businessman Mark Cuban and leading ENT physicians, the proceeds will be used to support the company's ongoing clinical programs, anticipated FDA approval and first commercial launch of a prescription wearable device using its noninvasive Vestibular System Masking (nVSM) technology for the treatment of chronic vertigo.